Press Releases ImmuPharma plc

Equities

IMM

GB0033711010

Market Closed - London S.E. Other stock markets 11:35:15 2024-04-26 am EDT			5-day change	1st Jan Change
2.14 ^GBX	0.00%		-8.94%	+28.37%

Apr. 02	Immupharma jumps amid new IP strategy for P140 technology platform	AN
Apr. 02	ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmuPharma : Incanthera Provides Commercial Update and Revenue Forecasts	Mar. 26	PU
ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments	Mar. 08	AQ
TR1 – Major Holding by Lanstead (Date: 28 December 2023)	Jan. 02	PU
ImmuPharma : TR1 – Major holding by Lanstead	Dec. 20	PU
ImmuPharma : Major shareholding by Lanstead via TR1	23-09-14	PU
ImmuPharma : Major shareholding from Lanstead Capital via TR1	23-09-06	PU
ImmuPharma : INTERIM RESULTS for the six months ended 30 June 2023	23-08-31	PU
ImmuPharma : Board strengthened Ahead of next phase of company progression	23-08-11	PU
ImmuPharma "absolutely delighted" to push on with new clinical trial	23-06-28	AQ
ImmuPharma : Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting	23-06-19	PU
Immupharma : Warrants Outstanding	23-06-16	PU
ImmuPharma : Notice of AGM & Annual Report & Accounts	23-06-06	PU
ImmuPharma "looking forward with quiet confidence" to FDA response	23-05-24	AQ
ImmuPharma : TR1 Lanstead holding 10 May 2023	23-05-11	PU
ImmuPharma : FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022	23-05-11	PU
ImmuPharma "looking forward" to upcoming FDA meetings	23-04-28	AQ
ImmuPharma : FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus	23-04-20	PU
ImmuPharma : receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP	23-04-12	PU
ImmuPharma : Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA	23-03-26	PU
ImmuPharma : Grant of Share Options	23-02-23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ImmuPharma plc

Equities

IMM

GB0033711010

Press Releases

Filters